Rybrevant Faspro is a new under-the-skin (subcutaneous) injection form of the cancer medicine Rybrevant (amivantamab). The FDA has now approved it in combination with another medicine called ...
The Food and Drug Administration (FDA) has approved Rybrevant Faspro™, a subcutaneous (SC) formulation of amivantamab for all indications approved for the ...
Rybrevant Faspro, a subcutaneous therapy, offers a faster, less invasive treatment for EGFR-mutated NSCLC, reducing administration time and reactions compared to intravenous methods. The PALOMA-3 ...
RYBREVANT FASPRO™, the first and only subcutaneous therapy for patients with EGFR-mutated NSCLC, reduces administration time from hours to minutes and significantly reduces administration-related ...
The U.S. Food and Drug Administration has approved Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) as the first and only subcutaneously administered therapy for patients with epidermal growth ...
The U.S. Food and Drug Administration (FDA) approved six new therapies in December 2025 for blood cancers, prostate cancer, ...
HORSHAM, Pa., Dec. 17, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) announced today that the U.S. Food and Drug Administration (FDA) approved RYBREVANT FASPRO™ (amivantamab and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback